Neumora Therapeutics (NMRA) to Release Quarterly Earnings on Tuesday

Neumora Therapeutics (NASDAQ:NMRA) will issue its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Neumora Therapeutics Stock Performance

NASDAQ NMRA opened at $13.54 on Friday. Neumora Therapeutics has a one year low of $8.33 and a one year high of $21.00. The business has a fifty day moving average price of $13.02 and a 200 day moving average price of $11.34. The company has a market cap of $2.17 billion, a P/E ratio of -5.29 and a beta of 3.92.

Insider Buying and Selling

In other news, insider Robert A. Lenz sold 30,788 shares of the firm’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total transaction of $363,606.28. Following the completion of the transaction, the insider now directly owns 339,205 shares in the company, valued at $4,006,011.05. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CFO Joshua Pinto sold 31,642 shares of Neumora Therapeutics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $11.78, for a total value of $372,742.76. Following the completion of the transaction, the chief financial officer now owns 154,658 shares in the company, valued at approximately $1,821,871.24. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Robert A. Lenz sold 30,788 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total value of $363,606.28. Following the transaction, the insider now directly owns 339,205 shares of the company’s stock, valued at approximately $4,006,011.05. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 110,538 shares of company stock valued at $1,390,513. Company insiders own 26.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Royal Bank of Canada reiterated an “outperform” rating and set a $29.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $18.00 to $15.00 in a research note on Tuesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a research report on Friday, October 18th. Finally, HC Wainwright initiated coverage on Neumora Therapeutics in a report on Tuesday, October 1st. They issued a “buy” rating and a $30.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Neumora Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $21.67.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.